Kezar Life Sciences Files 8-K
Ticker: KZR · Form: 8-K · Filed: Feb 27, 2025 · CIK: 1645666
| Field | Detail |
|---|---|
| Company | Kezar Life Sciences, INC. (KZR) |
| Form Type | 8-K |
| Filed Date | Feb 27, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-disclosure, sec-filing
Related Tickers: KZR
TL;DR
Kezar Life Sciences filed an 8-K on Feb 27, 2025, with corporate updates.
AI Summary
Kezar Life Sciences, Inc. filed an 8-K on February 27, 2025, reporting other events and financial statements. The filing details the company's principal executive offices located at 4000 Shoreline Court, Suite 300, South San Francisco, California, 94080.
Why It Matters
This 8-K filing indicates that Kezar Life Sciences is providing updates on its corporate activities and financial reporting to the SEC.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks.
Key Players & Entities
- Kezar Life Sciences, Inc. (company) — Registrant
- February 27, 2025 (date) — Date of earliest event reported
- 4000 Shoreline Court, Suite 300 (location) — Principal Executive Offices
- South San Francisco, California (location) — City and State of Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Kezar Life Sciences, Inc.?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of February 27, 2025.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on February 27, 2025.
Where are Kezar Life Sciences, Inc.'s principal executive offices located?
Kezar Life Sciences, Inc.'s principal executive offices are located at 4000 Shoreline Court, Suite 300, South San Francisco, California, 94080.
What is the company's IRS Employer Identification Number?
The company's IRS Employer Identification Number is 47-3366145.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 27, 2025 regarding Kezar Life Sciences, Inc. (KZR).